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Asia and the Pacific region is one of the world’s most
vibrant places in terms of economic growth and social
advancement. It captures many superlatives: the planet’s
highest proportion of young people, the largest mega-
cities in the world and Asia wins the crown of "global
growth leader" again and again. However, despite the
dynamism, some citizens are falling through the cracks.
This is particularly true for people who inject drugs
(PWID). With 3.15 million PWID, in terms of sheer num-
bers, East Asia and Southeast Asia has the largest injecting
drug problem in the world and is home to one in four
PWID globally [1].
People who inject drugs have multiple vulnerabilities—to
HIV, hepatitis, tuberculosis and other infectious diseases;
they account for an estimated 30 % of new HIV infections
outside sub-Saharan Africa. About a third of PWID are
living with HIV in Southwest Asia [1], and a number of
countries have reported HIV prevalence higher than 10 %
[2]. National figures often do not tell the full story, with
some localities reporting significantly higher prevalence. In
Cebu City, Philippines, HIV prevalence among PWID was
estimated at 52.3 % in 2013 [3], and in Faisalabad, Pakistan,
it was as high as 52.5 % in 2011 [4].
Scientific evidence shows that to respond to HIV and
other health risks of people who inject drugs, it is im-
portant to develop programmes which cater to their
needs. The Joint United Nations Programme on HIV/
AIDS (UNAIDS), the United Nations Office on Drugs
and Crime (UNODC) and the World Health
Organization (WHO) have recommended a package of
nine interventions, commonly referred to as the com-
prehensive approach to injecting drug use [5].
The first four interventions—needle-syringe programmes
(NSP), opioid substitution therapy (OST), HIV testing and
counselling and the provision of antiretroviral therapy
(ART)—are critical for effective national programmes.
There is compelling evidence that NSP and OST are effect-
ive in reducing the sharing of injecting equipment and
averting HIV infections. In combination with ART,
these interventions diminish HIV transmission, de-
crease mortality, reduce drug dependency and improve
quality of life.
Several countries in the region have taken these recom-
mendations to heart and implemented parts of the compre-
hensive harm reduction package. In the late 1990s, China
had a fast-growing HIV epidemic among people who inject
drugs and its health authorities began introducing OST
sites and needle-syringe programmes. By the end of 2014,
more than 700 OST sites were operating in China. HIV
incidence rate dropped by 87.6 % from 0.95 % in 2006 to
0.12 % in 2014 among those registered in the clinics [6].
Recently, India and Myanmar have also increased their
OST coverage.
Despite these pockets of success, the coverage of harm
reduction programmes remains inadequate in Asia and
the Pacific region. High coverage of needle-syringe pro-
grammes is defined by WHO, UNAIDS and UNODC as
more than 200 needles or syringes provided per PWID a
year. Only four countries reported reaching high cover-
age in 2014, and five reported that less than 50 % of
PWID used clean equipment for their last injection [2].
PWID frequently face stigma and discrimination when
seeking health services and are far less likely to receive
ART than others living with HIV due to social
marginalization and the flawed perception that they
are unable to adhere to treatment effectively. While
current national monitoring systems are not designed
to capture data on access to ART for PWID, a recent
review suggests that less than five PWID received
ART per 100 HIV-positive PWID [7].
Not only is coverage low, but there are worrying signs
that some countries with a high HIV burden among
PWID are scaling down harm reduction interventions
[8]. This is undoubtedly due to the phasing out of sup-
port by international donors with little new funds
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coming in from domestic sources. In Asia and the
Pacific, 81 % of harm reduction activities were funded by
international partners, primarily the Global Fund to
Fight AIDS, Tuberculosis and Malaria and key bilateral
partners [9].
Criminalization and punitive policies are often an
entrenched part of the drug rehabilitation landscape in
Asia and the Pacific region. The most common response
is the confinement of people who use drugs in compulsory
treatment and rehabilitation centres. In many centres, a
medical assessment of drug dependency is not undertaken
upon admission and evidence-informed treatment is
lacking for those with drug dependency. Where treat-
ment is provided, it is often not efficient, resulting in
high relapse rates upon release from the centres.
In March 2012, 12 UN agencies issued a joint state-
ment on compulsory drug detention and rehabilitation
centres, calling for their closure and replacement with
voluntary, evidence-informed and rights-based health
and social services in the community [10]. Malaysia has
taken the lead in making the change by transforming 22
compulsory detention centres for PWID into ‘Cure and
Care’ centres and establishing 10 clinics that provide
outpatient treatment [11].
Yet this move to voluntary community based treat-
ment and services is still the exception rather than the
rule. A paradigm shift is needed, moving from a punitive
approach to support, praise and encouragement. With
the world’s biggest population of PWID, the Asia-Pacific
region can demonstrate the entrepreneurial can-do spirit
it is known for and lead the way to ending the AIDS epi-
demic among people who inject drugs.
To achieve this, there is an urgent need to rapidly scale
up evidence-informed services for PWID in the next
5 years. This fast-track approach sets the following targets
to be reached by 2020:
 Ninety percent of PWID know their HIV status
 Ninety percent of PWID who know their status are
receiving treatment
 Ninety percent of PWID on treatment have a
suppressed viral load so their immune systems
remain strong
 Ninety percent coverage of HIV prevention services
for PWID
 Forty percent of PWID access opioid substitution
therapy
 Zero discrimination towards PWID
Countries should also make an effort to increase
access to naloxone through community-based distri-
bution to help reduce high rates of opioid overdose,
particularly where access to essential health services
for PWID is limited. In addition, access to hepatitis B
and C prevention, screening and treatment services
should be accelerated.
While these targets are ambitious, they are possible to
reach if countries:
 Replace compulsory drug detention and rehabilitation
centres with voluntary and community-based
treatment and services in a time-bound transition
plan developed with key stakeholders
 Increase domestic investment in a comprehensive
package of prevention, care and treatment services
for PWID
 Strengthen collaboration between drug control and
law enforcement officials and the health sector and
update legal and policy frameworks to allow the
expansion of HIV services to PWID
 Work on the intersection between injecting drug use
and high-risk sexual behaviour, especially where sex
work is undertaken to buy drugs or accessed by men
who have sex with men, sex workers and transgender
people
This approach is transformative. If business as usual
continues, it is estimated that there will be around
20,000 new HIV infections among PWID in the Asia and
Pacific region by 2030, but with a Fast-Track approach
that number could be cut by more than half. These
numbers speak for themselves. The time to act is now.
The region has achieved much, and we are confident
that with visionary leadership, solid partnerships be-
tween government and civil society, evidence-informed
and targeted allocation of resources and bold action, it
can become the first in the world to end the AIDS epi-
demic in PWID.
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